Bin Yang

This study develops LD5095, a novel cereblon-recruiting RIPK1 degrader, showing potent RIPK1 degradation and tumor sensitization to immune checkpoint inhibitors.

This study designs and evaluates a novel RIPK1 degrader, LD5097, showing potent degradation activity, favorable pharmacokinetics, and enhanced antitumor effects in cancer models.

COOKIE-Pro quantifies covalent inhibitor binding kinetics across the proteome, revealing off-targets and kinetic parameters for BTK inhibitors.